AtriCure receives regulatory approval to sell AtriClip devices in China

image credit- shutterstock

AtriCure, Inc. a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced that it has received regulatory approval from the National Medical Products Administration (NMPA) of China to market and sell several models of its AtriClip Left Atrial Appendage (LAA) Exclusion System.

The AtriClip device is an innovative solution designed to exclude and electrically isolate the left atrial appendage during cardiac surgery, providing life-saving treatments for patients suffering from Afib and associated risks. AtriClip devices have been successfully used in over 550,000 patients worldwide and are recognized for a unique design, which ensures complete exclusion, and eventual elimination of the LAA via the process of ischemic necrosis.

The approval of the AtriClip device in China is based on robust clinical data demonstrating its safety and efficacy. With this approval, AtriCure plans to partner with leading medical institutions and professionals in China to provide comprehensive training and support, ensuring the highest standards of patient care. The company will also work closely with Chinese regulatory authorities to facilitate the introduction of additional innovative products in the future.

Michael Carrel, President and CEO of AtriCure, said “While patients have been benefitting from our surgical ablation devices in China for many years, this is a major step forward in our global expansion strategy. China represents a significant market opportunity, and we look forward to working with our partners and healthcare providers across the country to deliver our innovative solutions.”